Mayne Pharma Group 주식 주식분석 | 주식가격 | 뉴스 | MYX.AX | AU000000MYX0 | A1C821

날짜	Mayne Pharma Group 주식 가격
	4.78 undefined
	4.95 undefined
	4.77 undefined
	4.85 undefined
	4.48 undefined
	4.26 undefined
	4.45 undefined
	4.65 undefined
	4.69 undefined
	4.89 undefined
	4.90 undefined
	4.92 undefined
	5.29 undefined
	5.20 undefined
	5.10 undefined
	4.43 undefined
	4.42 undefined
	4.25 undefined
	4.38 undefined
	4.44 undefined
	4.32 undefined

날짜	Mayne Pharma Group 매출	Mayne Pharma Group EBIT	Mayne Pharma Group 이익
2027e	562.27 백만 undefined	28.66 백만 undefined	19.08 백만 undefined
2026e	480.91 백만 undefined	-1.91 백만 undefined	-4.55 백만 undefined
2025e	438.85 백만 undefined	-22.22 백만 undefined	-19.08 백만 undefined
2024	395.47 백만 undefined	-155.3 백만 undefined	-174.23 백만 undefined
2023	190.31 백만 undefined	-165.45 백만 undefined	117.25 백만 undefined
2022	157.61 백만 undefined	-55.87 백만 undefined	-281.29 백만 undefined
2021	401.47 백만 undefined	20.55 백만 undefined	-208.42 백만 undefined
2020	457.77 백만 undefined	4.86 백만 undefined	-92.79 백만 undefined
2019	526.22 백만 undefined	52.46 백만 undefined	-279.2 백만 undefined
2018	530.43 백만 undefined	62.72 백만 undefined	-133.98 백만 undefined
2017	572.6 백만 undefined	129.82 백만 undefined	88.57 백만 undefined
2016	267.28 백만 undefined	58.8 백만 undefined	37.36 백만 undefined
2015	141.42 백만 undefined	19.4 백만 undefined	7.76 백만 undefined
2014	143.3 백만 undefined	29.8 백만 undefined	21.3 백만 undefined
2013	84.1 백만 undefined	11.2 백만 undefined	-2.8 백만 undefined
2012	52.5 백만 undefined	6 백만 undefined	6.2 백만 undefined
2011	50.1 백만 undefined	2.4 백만 undefined	1.7 백만 undefined
2010	36.7 백만 undefined	2 백만 undefined	3.3 백만 undefined
2009	400,000 undefined	-4.7 백만 undefined	-3.8 백만 undefined
2008	800,000 undefined	-3.4 백만 undefined	-3.5 백만 undefined
2007	100,000 undefined	-1.8 백만 undefined	-1.8 백만 undefined
2006	0 undefined	0 undefined	0 undefined

	매출	EBIT	이익
2006	0 AUD	0 AUD	0 AUD
2007	100,000 AUD	-1.8 백만 AUD	-1.8 백만 AUD
2008	800,000 AUD	-3.4 백만 AUD	-3.5 백만 AUD
2009	400,000 AUD	-4.7 백만 AUD	-3.8 백만 AUD
2010	36.7 백만 AUD	2 백만 AUD	3.3 백만 AUD
2011	50.1 백만 AUD	2.4 백만 AUD	1.7 백만 AUD
2012	52.5 백만 AUD	6 백만 AUD	6.2 백만 AUD
2013	84.1 백만 AUD	11.2 백만 AUD	-2.8 백만 AUD
2014	143.3 백만 AUD	29.8 백만 AUD	21.3 백만 AUD
2015	141.42 백만 AUD	19.4 백만 AUD	7.76 백만 AUD
2016	267.28 백만 AUD	58.8 백만 AUD	37.36 백만 AUD
2017	572.6 백만 AUD	129.82 백만 AUD	88.57 백만 AUD
2018	530.43 백만 AUD	62.72 백만 AUD	-133.98 백만 AUD
2019	526.22 백만 AUD	52.46 백만 AUD	-279.2 백만 AUD
2020	457.77 백만 AUD	4.86 백만 AUD	-92.79 백만 AUD
2021	401.47 백만 AUD	20.55 백만 AUD	-208.42 백만 AUD
2022	157.61 백만 AUD	-55.87 백만 AUD	-281.29 백만 AUD
2023	190.31 백만 AUD	-165.45 백만 AUD	117.25 백만 AUD
2024	395.47 백만 AUD	-155.3 백만 AUD	-174.23 백만 AUD
2025e	438.85 백만 AUD	-22.22 백만 AUD	-19.08 백만 AUD
2026e	480.91 백만 AUD	-1.91 백만 AUD	-4.55 백만 AUD
2027e	562.27 백만 AUD	28.66 백만 AUD	19.08 백만 AUD

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0	15.3	11.5	7.9	19.7	5.8	11.6	18.9	14.8	59.2	47.48	63.03	87.31	89	137.79	97.98	96.67	220.14	149.28
0	0.1	0	0	5.1	5	3	23.9	28.8	62.51	91.54	223.56	251.67	250.98	191.99	173.47	259.04	177.4	176.47
0	0	0	0	0.9	1.3	0.8	2.3	2	5.1	7.97	10.24	23.25	6.12	41.25	17.51	23.3	32.12	31.21
0	0	0	0	6.5	6.4	7.2	13.6	17.2	22.44	38.94	106.39	82.16	100.35	94	102.51	108.91	82.7	74.63
0	0.1	0.1	0	0.3	0.3	0.6	3.1	3	7.56	891.11	18.89	36.38	25.49	25.93	25.06	23.7	41.27	29.01
0	0.02	0.01	0.01	0.03	0.02	0.02	0.06	0.07	0.16	1.08	0.42	0.48	0.47	0.49	0.42	0.51	0.55	0.46
0	0.1	0	0	21	21.5	22.2	55	53.4	59.6	84.45	189.27	230.05	236.03	238.24	221.6	225.86	51.48	53.33
0	0	0	0	0	0	0	0	4.1	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12.59	0	0	0
0	0	0	0	0.01	0.01	0	0.07	0.09	0.24	0.27	1.18	1.03	0.78	0.94	0.62	0.41	0.62	0.57
0	0	0	0	0.4	0.4	0.4	47.2	47.5	58.44	60.12	58.22	20.62	21.73	22.17	20.35	22.13	0	0
0	0	0	0	3.3	5.2	4.3	1	1.3	9.57	31.8	61.2	65.16	130.13	133.7	176.32	122.94	24.98	60.68
0	0	0	0	0.04	0.03	0.03	0.17	0.2	0.37	0.45	1.49	1.35	1.16	1.33	1.05	0.78	0.69	0.68
0	0.02	0.01	0.01	0.07	0.05	0.05	0.23	0.27	0.53	1.53	1.91	1.83	1.64	1.83	1.46	1.29	1.25	1.14

0	0.02	0.02	0.02	0.03	0.03	0.03	0.12	0.14	0.26	0.26	1.13	1.13	1.14	1.24	1.24	1.24	1.23	1.22
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-1.4	-4.4	-8.2	-4.1	-7.7	-1.4	-4.3	18.3	27.41	70.66	160.97	40.62	-232.35	-318.2	-518.89	-794.57	-716.96	-888.56
0	0	0	0	0	0	0	6.8	3.4	27.63	29.93	12.47	54.09	99.51	117.17	48.71	101.91	117.62	118.53
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.01	0.01	0.01	0.03	0.02	0.03	0.12	0.16	0.31	0.36	1.3	1.23	1.01	1.04	0.77	0.55	0.63	0.45
0	0.2	0.1	0.1	2.2	2.1	2.9	6.8	7.1	51.57	64.05	66.59	63.89	50.44	29.84	42.36	63.57	32.03	20.87
0	0	0	0	0	0	0	0	6.6	6.52	49.15	72.73	79.25	68.44	70.49	63.78	113.19	195.87	179.85
0	0.8	0.1	0.2	13.4	10.5	9.4	27.8	14.3	36.98	910.63	40.57	37.53	41.56	74.08	62.34	44.55	68.64	109.39
0	0	0	0	0	0	0	0	0	0	0	0	0	36.62	41.23	42.16	63.11	10.81	0
0	0	0	0	7.6	2.3	0	7.5	2.4	0	0.5	13.12	0.06	14.26	3.61	11.89	344.88	3.62	3.82
0	0	0	0	0.02	0.01	0.01	0.04	0.03	0.1	1.02	0.19	0.18	0.21	0.22	0.22	0.63	0.31	0.31
0	0	0	0	1	0	0	39.2	45.7	62.75	76.33	327.12	374.13	318.5	353.21	292.78	5.67	33.08	35
0	0	0	0	5.5	4.5	3.7	20.6	21.8	41.35	41.64	56.91	34.03	31.36	28.98	13.46	6.03	7.8	7.35
0	0	0	0	15.9	10.1	7.3	10.6	8.7	7.56	7.27	18.57	6.46	61.07	181.42	162.84	108.68	261.16	332.7
0	0	0	0	22.4	14.6	11	70.4	76.2	111.67	125.24	402.6	414.63	410.93	563.61	469.08	120.38	302.04	375.05
0	0	0	0	0.05	0.03	0.02	0.11	0.11	0.21	1.15	0.6	0.6	0.62	0.78	0.69	0.75	0.61	0.69
0	0.02	0.01	0.01	0.07	0.05	0.05	0.23	0.27	0.52	1.51	1.9	1.82	1.63	1.82	1.46	1.3	1.25	1.14

2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-281	117
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	78	70
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	68	69
0	0	0	-22	0	0	-5	-4	-8	-20	10	-15	-27	-30	-22	-32	-38
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	200	-381
0	0	0	0	0	0	-2	-3	-4	-1	-10	-15	-14	-13	0	0	0
0	0	0	0	-2	0	-2	-3	-7	-26	-57	-7	21	-1	10	7	-4
-1	-3	-3	10	4	13	5	25	22	53	-15	121	106	99	58	-7	-42
0	0	0	0	-2	-2	-21	-31	-83	-62	-1,083	-94	-81	-47	-25	-11	-219
0	0	0	-18	-2	-5	-125	-50	-95	-83	-1,097	-118	-91	-55	-49	-28	473
0	0	0	-18	0	-2	-104	-18	-11	-20	-13	-24	-9	-8	-24	-16	693
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	8	-5	-2	40	2	1	13	269	18	-22	4	-28	37	-375
16	0	0	14	1	0	89	18	118	0	892	1	7	0	0	0	-6
0.02	0	0	0.02	-0.01	-0	0.13	0.02	0.12	0.02	1.13	0.02	-0.02	0	-0.04	0.03	-0.43
0	0	0	-1	-6	0	-4	0	-4	3	-32	0	0	0	-11	-9	-4
0	0	0	0	-4	0	0	0	0	0	0	0	0	0	0	0	-45
13	-7	-8	44	-7	18	22	32	86	89	56	184	129	194	30	16	-3
-1.3	-3	-3.6	9.9	2	10.9	-15.4	-6.1	-61.55	-9.72	-1,099.52	27.16	24.69	52.66	33.77	-19.06	-262.3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Mayne Pharma Group 브루토마진	Mayne Pharma Group 이익 마진	Mayne Pharma Group EBIT-마진	Mayne Pharma Group 이익 마진
2027e	57.11 %	5.1 %	3.39 %
2026e	57.11 %	-0.4 %	-0.95 %
2025e	57.11 %	-5.06 %	-4.35 %
2024	57.11 %	-39.27 %	-44.06 %
2023	47.51 %	-86.94 %	61.61 %
2022	47.74 %	-35.45 %	-178.47 %
2021	45.5 %	5.12 %	-51.92 %
2020	46.38 %	1.06 %	-20.27 %
2019	60.13 %	9.97 %	-53.06 %
2018	53.61 %	11.82 %	-25.26 %
2017	56.82 %	22.67 %	15.47 %
2016	63.79 %	22 %	13.98 %
2015	56.56 %	13.71 %	5.49 %
2014	52.41 %	20.8 %	14.86 %
2013	47.21 %	13.32 %	-3.33 %
2012	44.19 %	11.43 %	11.81 %
2011	46.31 %	4.79 %	3.39 %
2010	47.96 %	5.45 %	8.99 %
2009	100 %	-1,175 %	-950 %
2008	57.11 %	-425 %	-437.5 %
2007	57.11 %	-1,800 %	-1,800 %
2006	57.11 %	0 %	0 %

	브루토마진	EBIT-마진	이익 마진
2006	57.11 %	0 %	0 %
2007	57.11 %	-1,800 %	-1,800 %
2008	57.11 %	-425 %	-437.5 %
2009	100 %	-1,175 %	-950 %
2010	47.96 %	5.45 %	8.99 %
2011	46.31 %	4.79 %	3.39 %
2012	44.19 %	11.43 %	11.81 %
2013	47.21 %	13.32 %	-3.33 %
2014	52.41 %	20.8 %	14.86 %
2015	56.56 %	13.71 %	5.49 %
2016	63.79 %	22 %	13.98 %
2017	56.82 %	22.67 %	15.47 %
2018	53.61 %	11.82 %	-25.26 %
2019	60.13 %	9.97 %	-53.06 %
2020	46.38 %	1.06 %	-20.27 %
2021	45.5 %	5.12 %	-51.92 %
2022	47.74 %	-35.45 %	-178.47 %
2023	47.51 %	-86.94 %	61.61 %
2024	57.11 %	-39.27 %	-44.06 %
2025e	57.11 %	-5.06 %	-4.35 %
2026e	57.11 %	-0.4 %	-0.95 %
2027e	57.11 %	5.1 %	3.39 %

날짜	Mayne Pharma Group 주당 매출	Mayne Pharma Group EBIT 당 주식	Mayne Pharma Group 주당 이익
2027e	6.61 undefined	0 undefined	0.22 undefined
2026e	5.65 undefined	0 undefined	-0.05 undefined
2025e	5.16 undefined	0 undefined	-0.22 undefined
2024	4.97 undefined	-1.95 undefined	-2.19 undefined
2023	2.32 undefined	-2.01 undefined	1.43 undefined
2022	1.92 undefined	-0.68 undefined	-3.42 undefined
2021	5.11 undefined	0.26 undefined	-2.65 undefined
2020	5.99 undefined	0.06 undefined	-1.21 undefined
2019	7.13 undefined	0.71 undefined	-3.79 undefined
2018	7.25 undefined	0.86 undefined	-1.83 undefined
2017	7.84 undefined	1.78 undefined	1.21 undefined
2016	0.31 undefined	0.07 undefined	0.04 undefined
2015	0.2 undefined	0.03 undefined	0.01 undefined
2014	0.22 undefined	0.05 undefined	0.03 undefined
2013	0.19 undefined	0.03 undefined	-0.01 undefined
2012	0.24 undefined	0.03 undefined	0.03 undefined
2011	0.23 undefined	0.01 undefined	0.01 undefined
2010	0.21 undefined	0.01 undefined	0.02 undefined
2009	0 undefined	-0.04 undefined	-0.04 undefined
2008	0.01 undefined	-0.03 undefined	-0.03 undefined
2007	0 undefined	-0.03 undefined	-0.03 undefined
2006	0 undefined	0 undefined	0 undefined

	주당 매출	EBIT 당 주식	주당 이익
2006	0 AUD	0 AUD	0 AUD
2007	0 AUD	-0.03 AUD	-0.03 AUD
2008	0.01 AUD	-0.03 AUD	-0.03 AUD
2009	0 AUD	-0.04 AUD	-0.04 AUD
2010	0.21 AUD	0.01 AUD	0.02 AUD
2011	0.23 AUD	0.01 AUD	0.01 AUD
2012	0.24 AUD	0.03 AUD	0.03 AUD
2013	0.19 AUD	0.03 AUD	-0.01 AUD
2014	0.22 AUD	0.05 AUD	0.03 AUD
2015	0.2 AUD	0.03 AUD	0.01 AUD
2016	0.31 AUD	0.07 AUD	0.04 AUD
2017	7.84 AUD	1.78 AUD	1.21 AUD
2018	7.25 AUD	0.86 AUD	-1.83 AUD
2019	7.13 AUD	0.71 AUD	-3.79 AUD
2020	5.99 AUD	0.06 AUD	-1.21 AUD
2021	5.11 AUD	0.26 AUD	-2.65 AUD
2022	1.92 AUD	-0.68 AUD	-3.42 AUD
2023	2.32 AUD	-2.01 AUD	1.43 AUD
2024	4.97 AUD	-1.95 AUD	-2.19 AUD
2025e	5.16 AUD	0 AUD	-0.22 AUD
2026e	5.65 AUD	0 AUD	-0.05 AUD
2027e	6.61 AUD	0 AUD	0.22 AUD

	주식 수량
2006	29.4 백만 Aktien
2007	62 백만 Aktien
2008	106.8 백만 Aktien
2009	106.8 백만 Aktien
2010	178.7 백만 Aktien
2011	215.1 백만 Aktien
2012	214.6 백만 Aktien
2013	443.3 백만 Aktien
2014	645.6 백만 Aktien
2015	715.45 백만 Aktien
2016	858 백만 Aktien
2017	73.02 백만 Aktien
2018	73.14 백만 Aktien
2019	73.75 백만 Aktien
2020	76.47 백만 Aktien
2021	78.58 백만 Aktien
2022	82.3 백만 Aktien
2023	82.18 백만 Aktien
2024	79.62 백만 Aktien
2025e	79.62 백만 Aktien
2026e	79.62 백만 Aktien
2027e	79.62 백만 Aktien

날짜	Mayne Pharma Group 배당금
2027e	0.27 undefined
2026e	-0.06 undefined
2025e	-0.27 undefined
2023	0.78 undefined
2011	0.01 undefined
2010	0.02 undefined

	배당금	배당금 (추정)
2006	0 AUD	0 AUD
2007	0 AUD	0 AUD
2008	0 AUD	0 AUD
2009	0 AUD	0 AUD
2010	0.02 AUD	0 AUD
2011	0.01 AUD	0 AUD
2012	0 AUD	0 AUD
2013	0 AUD	0 AUD
2014	0 AUD	0 AUD
2015	0 AUD	0 AUD
2016	0 AUD	0 AUD
2017	0 AUD	0 AUD
2018	0 AUD	0 AUD
2019	0 AUD	0 AUD
2020	0 AUD	0 AUD
2021	0 AUD	0 AUD
2022	0 AUD	0 AUD
2023	0.78 AUD	0 AUD
2024	0 AUD	0 AUD
2025e	0 AUD	-0.27 AUD
2026e	0 AUD	-0.06 AUD
2027e	0 AUD	0.27 AUD

날짜	Mayne Pharma Group 배당률
2027e	121.05 %
2026e	121.06 %
2025e	121.06 %
2024	121.05 %
2023	121.06 %
2022	121.06 %
2021	121.03 %
2020	121.1 %
2019	121.05 %
2018	120.92 %
2017	121.34 %
2016	120.88 %
2015	120.54 %
2014	122.6 %
2013	119.51 %
2012	119.51 %
2011	128.79 %
2010	110.23 %
2009	119.51 %
2008	119.51 %
2007	119.51 %
2006	119.51 %

	배당률
2006	119.51 %
2007	119.51 %
2008	119.51 %
2009	119.51 %
2010	110.23 %
2011	128.79 %
2012	119.51 %
2013	119.51 %
2014	122.6 %
2015	120.54 %
2016	120.88 %
2017	121.34 %
2018	120.92 %
2019	121.05 %
2020	121.1 %
2021	121.03 %
2022	121.06 %
2023	121.06 %
2024	121.05 %
2025e	121.06 %
2026e	121.06 %
2027e	121.05 %

EPS-예상치	EPS-실제	보고 분기
-0.23	-0.23 (-3.91 %)	2024 Q4
-0.47	-0.51 (-8.21 %)	2024 Q2
-0.58	-0.12 (78.82 %)	2023 Q4
-0.93	0.15 (115.93 %)	2023 Q2
-0.22	-1.48 (-566.07 %)	2022 Q4
-0.51	-0.2 (60.4 %)	2021 Q4
-8.08	0.42 (105.2 %)	2021 Q2
0.03	0.01 (-71.72 %)	2015 Q2

%-지분	이름	주식	변경
7.55606 %	Viburnum Funds Pty Ltd	6,428,268	67,676
6.22052 %	Mathieson (Bruce Lawrence)	5,292,066	5,183,477
6.03456 %	Goldman Sachs Financial Markets Pty. Ltd.	5,133,856	4,003,980
5.01268 %	Insignia Financial Ltd	4,264,499	4,264,499
4.96250 %	Estetra SPRL	4,221,815	4,221,814
2.66385 %	The Vanguard Group, Inc.	2,266,253	76,895
1.99999 %	UBS Fund Management (Switzerland) AG	1,701,480	1,701,480
1.52287 %	Gft 2 Co. Pty. Ltd.	1,295,569	-28,300
1.39255 %	Vanguard Investments Australia Ltd.	1,184,699	758
1.29310 %	Dimensional Fund Advisors, L.P.	1,100,096	0
0.94035 %	IVL Group Pty. Ltd.	800,000	0
0.88158 %	Vivnat (Curtin) Pty. Ltd.	750,000	250,000
0.75323 %	DFA Australia Ltd.	640,803	-11,209
0.61361 %	R & R Corbett Pty Ltd	522,028	0
0.58772 %	Y S Chains Pty. Ltd.	500,000	-535,000
0.56238 %	UBS Asset Management (Australia) Ltd.	478,445	44,430
0.54658 %	Retzos Executive Pty. Ltd.	465,000	40,000
0.48660 %	Norges Bank Investment Management (NBIM)	413,972	-142,430
0.47018 %	Tzimokas (Kon)	400,000	0
0.42977 %	Paltoglou (Peter)	365,626	-79,695
0.41669 %	Wal Assets Pty. Ltd.	354,500	-45,500
0.35263 %	Zhang (Yunsong)	300,000	300,000
0.35263 %	Birbal Investments Pty. Ltd.	300,000	300,000
0.34705 %	Belgravia Strategic Equities Pty. Ltd.	295,250	295,250
0.29091 %	Dimensional Fund Advisors, Ltd.	247,490	0
0.17799 %	Charles Schwab Investment Management, Inc.	151,427	-1,340
0.11246 %	MLC Asset Management	95,675	-7
0.07750 %	Condella (Frank Charles Jr)	65,929	7,154
0.07153 %	O'Brien (Shawn Patrick)	60,857	23,816
0.06444 %	BlackRock Investment Management (Australia) Ltd.	54,822	0
0.05395 %	State Street Global Advisors (US)	45,900	-690
0.04467 %	MacFarlane (Kathryn)	38,000	18,000
0.04402 %	American Century Investment Management, Inc.	37,450	0
0.04038 %	BetaShares Capital Ltd.	34,356	284
0.03731 %	Robinson (Bruce Gregory)	31,745	0
0.02597 %	Blake (Patrick J)	22,097	0
0.02511 %	Custin (Ann)	21,362	12,287
0.02351 %	Myers Carolyn J	20,000	0
0.01316 %	MLC Investments Limited	11,192	978
0.01016 %	State Street Global Advisors Australia Ltd.	8,640	-93
0.00257 %	Goldman Sachs Asset Management, L.P.	2,190	0
0.00122 %	Vanguard Global Advisers LLC	1,040	0
0.00111 %	Mackenzie Investments	942	-4,958
0.00071 %	Connor, Clark & Lunn Investment Management Ltd.	603	165
0.00000 %	Goldman Sachs Asset Management B.V.	2	0
0 %	RAM Active Investments S.A.	0	-4,452
0 %	Heritage Wealth Advisors, LLC	0	-1,000
0 %	KLP Fondsforvaltning AS	0	-9,076
0 %	Geode Capital Management, L.L.C.	0	-19,079
0 %	Northern Trust Global Investments Limited	0	-9,250
0 %	BlackRock Asset Management Canada Limited	0	-27,554
0 %	Evli Fund Management Company Ltd.	0	-1,040
0 %	Pictet Asset Management Ltd.	0	-3,945
0 %	BlackRock Investment Management (UK) Ltd.	0	-6,406
0 %	UBS Asset Management (UK) Ltd.	0	-34,050
0 %	Legal & General Investment Management Ltd.	0	-4,015
0 %	AXA Investment Managers UK Ltd.	0	-59,020
0 %	BlackRock Advisors (UK) Limited	0	-40,915
0 %	Z¿rcher Kantonalbank (Asset Management)	0	-16,769
0 %	DWS Investment GmbH	0	-9,071
0 %	UBS Asset Management (Switzerland)	0	-39,604
0 %	State Street Global Advisors Ireland Limited	0	-16,084
0 %	BlackRock Institutional Trust Company, N.A.	0	-682,094
0 %	Florida State Board of Administration	0	-21,743
0 %	Nuveen LLC	0	-37,514
0 %	Bessemer Trust Company, N.A. (US)	0	-13,545
0 %	AllianceBernstein L.P.	0	-305
0 %	California State Teachers Retirement System	0	-76,629
0 %	Avantis Investors	0	-68,940
0 %	Macquarie Investment Management Global Ltd.	0	-2,463

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
HSBC Holdings	공급업체고객	0,83	-0,03	0,62	-0,27	-0,50	-0,47
Mithra Pharmaceuticals	공급업체고객	0,71	-0,71	-0,18	0,33	0,58	0,41
Teligent	공급업체고객	0,66	-0,26	-0,15	0,60
JPMorgan Chase	공급업체고객	0,48	-0,41	0,01	0,54	0,58	-0,29
Citigroup	공급업체고객	0,36	0,26	0,03	0,44	0,72	0,03
X4 Pharmaceuticals	공급업체고객	0,10	-0,74	-0,83	0,39	0,82	0,75
SAWAI GROUP HOLDINGS	공급업체고객	-0,62	-0,70	-0,39	0,22	0,58	0,70

What values and corporate philosophy does Mayne Pharma Group represent?

Mayne Pharma Group Ltd is a pharmaceutical company that values innovation, integrity, and patient care. With a commitment to developing high-quality, affordable medications, Mayne Pharma Group Ltd aims to improve the health and well-being of individuals worldwide. The company's corporate philosophy revolves around delivering effective solutions through research, development, and manufacturing of pharmaceutical products. Mayne Pharma Group Ltd prioritizes transparency, ethical practices, and collaboration in its operations, ensuring compliance with regulatory standards. By focusing on customer needs and advancing pharmaceutical technologies, Mayne Pharma Group Ltd continues to build a reputation as a trusted and forward-thinking healthcare organization.

In which countries and regions is Mayne Pharma Group primarily present?

Mayne Pharma Group Ltd primarily operates in various countries and regions around the world. The company has a strong presence in Australia, where it is headquartered, and it also has a significant presence in the United States. With a focus on developing, manufacturing, and marketing branded and generic pharmaceutical products, Mayne Pharma Group Ltd serves customers and healthcare professionals in these key markets. Additionally, the company's global reach extends to other regions, including Europe and Asia, where it actively pursues business opportunities and fosters growth. Mayne Pharma Group Ltd's international presence underscores its commitment to delivering high-quality healthcare solutions to a diverse range of patients globally.

What significant milestones has the company Mayne Pharma Group achieved?

Mayne Pharma Group Ltd has achieved significant milestones in its journey. Some notable accomplishments include the acquisition of Metrics Contract Services, a contract development and manufacturing organization. This strategic move expanded the company's capability to offer a full-service platform for pharmaceutical development and manufacturing. Mayne Pharma also received FDA approval for various generic and specialty pharmaceutical products, further strengthening its market presence in the United States. Additionally, the company successfully launched new products, such as Doryx, in the dermatology segment, and secured international distribution agreements. Mayne Pharma Group Ltd continues to strive for innovative solutions in the pharmaceutical industry to enhance shareholder value and meet patient needs.

What is the history and background of the company Mayne Pharma Group?

Mayne Pharma Group Ltd is an Australian pharmaceutical company with a rich history and background. Founded in 1845 as FH Faulding & Co, it has established itself as a reputable player in the industry. In 2015, the company acquired the generic products division of a large U.S. pharmaceutical company, strengthening its global presence. Mayne Pharma Group Ltd specializes in the development and manufacture of generic and specialty pharmaceutical products, focusing on areas such as oncology, dermatology, and women's health. With a commitment to quality and innovation, Mayne Pharma Group Ltd continues to make significant contributions to the healthcare sector globally.

Who are the main competitors of Mayne Pharma Group in the market?

The main competitors of Mayne Pharma Group Ltd in the market include companies like Teva Pharmaceutical Industries Ltd, Fagron NV, and Bio-Pharmaceutics, Inc. These companies operate in the pharmaceutical industry, focusing on generic drugs and specialty pharmaceuticals, similar to Mayne Pharma Group Ltd. By constantly monitoring and analyzing competition, Mayne Pharma Group Ltd strives to maintain its position and market share through strategic business decisions and product innovations.

In which industries is Mayne Pharma Group primarily active?

Mayne Pharma Group Ltd is primarily active in the pharmaceutical industry.

What is the business model of Mayne Pharma Group?

Mayne Pharma Group Ltd operates as a pharmaceutical company. Its business model revolves around developing, manufacturing, and distributing branded and generic prescription pharmaceuticals. Mayne Pharma specializes in providing contract development and manufacturing services to customers worldwide. By leveraging its expertise, capabilities, and global reach, Mayne Pharma aims to provide cost-effective and high-quality pharmaceutical products. The company focuses on various therapeutic areas, including cardiology, oncology, women's health, dermatology, and specialty products, catering to the needs of patients and healthcare professionals. Mayne Pharma Group Ltd strives to deliver innovative healthcare solutions and improve patient outcomes through its comprehensive business model.

Mayne Pharma Group 2024의 P/E 비율은 얼마입니까?

Mayne Pharma Group의 P/E 비율은 -2.18입니다.

Mayne Pharma Group 2024의 KUV는 얼마입니까?

Mayne Pharma Group의 P/S 비율은 0.96입니다.

Mayne Pharma Group의 AlleAktien 품질 점수는 얼마인가요?

Mayne Pharma Group에 대한 AlleAktien 품질 점수는 3/10입니다.

Mayne Pharma Group 2024의 매출은 얼마인가요?

Mayne Pharma Group 매출은 395.47 백만 AUD입니다.

Mayne Pharma Group 2024의 이익은 얼마인가요?

Mayne Pharma Group 이익은 -174.23 백만 AUD입니다.

Mayne Pharma Group은 무엇을 하나요?

Mayne Pharma Group Ltd is an Australian pharmaceutical company headquartered in Salisbury, South Australia. It was founded in 2015 through the merger of Mayne Pharma Limited and Hospira Australia Pty Ltd. The company specializes in the development, manufacturing, and marketing of generic and specialized pharmaceutical products. Overall, the company operates in four main business segments: generics, specialized products, contract manufacturing, and distribution in the United States. Mayne Pharma's generics division produces a wide range of pharmaceutical products in various categories such as cardiology, gastroenterology, analgesics, and antibiotics. Mayne Pharma is also involved in the manufacture of generics with controlled release of active ingredients and long-acting generics. Mayne Pharma's specialized products are medicines used to treat rare or chronic diseases and often have higher added value than standard generics. This includes products in the fields of dermatology, oncology, endocrinology, urology, and psychiatry. Mayne Pharma also operates contract manufacturing, using its own infrastructure to manufacture products on behalf of third parties. Mayne Pharma's contract manufacturing offers both small and large molecule products. This option allows companies to manufacture their own products without having to build their own production and development system. In the United States, Mayne Pharma is involved in the distribution of pharmaceutical products and operates a distribution channel in the industry. This expands Mayne Pharma's portfolio with commercially attractive and acquired active ingredients and excipients. Mayne Pharma has a strong portfolio of products and assets to make it a leading provider of generic and specialized pharmaceuticals. The company also has a solid pipeline of compounds in various stages to support future growth. Mayne Pharma's success is based on a combination of high quality standards, competitive prices, a strong pipeline portfolio, and a dedicated strategic partnership with other companies in the industry. Mayne Pharma is focused on providing its customers with high quality and affordable medications and strengthening its leadership position in global markets.

Mayne Pharma Group 배당금은 얼마입니까?

Mayne Pharma Group은(는) 연간 번의 배당을 통해 0 AUD의 배당금을 지급합니다.

Mayne Pharma Group이 얼마나 자주 배당을 지급하나요?

Mayne Pharma Group의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Mayne Pharma Group ISIN이 무엇입니까?

Mayne Pharma Group의 ISIN은 AU000000MYX0입니다.

Mayne Pharma Group WKN은 무엇인가요?

Mayne Pharma Group의 WKN은 A1C821입니다.

Mayne Pharma Group 티커는 무엇인가요?

Mayne Pharma Group의 티커는 MYX.AX입니다.

Mayne Pharma Group이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Mayne Pharma Group은(는) 0.78 AUD 의 배당금을 지급했습니다. 이는 약 16.26 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Mayne Pharma Group은(는) -0.27 AUD의 배당금을 지급할 것으로 예상됩니다.

Mayne Pharma Group의 배당 수익률은 얼마입니까?

Mayne Pharma Group의 현재 배당 수익률은 16.26 %입니다.

Mayne Pharma Group의 배당금은 언제 지급되나요?

Mayne Pharma Group은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Mayne Pharma Group의 배당금은 얼마나 안전한가요?

Mayne Pharma Group은(는) 지난 1년 동안 매년 배당금을 지급했습니다.

Mayne Pharma Group의 배당금은 얼마입니까?

향후 12개월 동안 -0.27 AUD의 배당금이 예상됩니다. 이는 배당수익률 -5.68 %에 해당합니다.

Mayne Pharma Group이(가) 속해 있는 섹터는 어디인가요?

Mayne Pharma Group은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Mayne Pharma Group kaufen, um die vorherige Dividende zu erhalten?

Mayne Pharma Group의 마지막 배당금을 0.777 AUD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Mayne Pharma Group의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Mayne Pharma Group의 2023년도 배당금은 얼마였습니까?

2023년에 Mayne Pharma Group는 0 AUD를 배당금으로 지급했습니다.

Mayne Pharma Group는 어떤 화폐로 배당금을 지급하나요?

Mayne Pharma Group의 배당금은 AUD에 지급됩니다.

Scope 1 - 직접 방출
스코프 2 - 구매한 에너지로부터의 간접적인 배출
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율	45
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

증권거래소	Mayne Pharma Group 티커
ASX	MYX.AX
뒤셀도르프	HG6.DU
프랑크푸르트	HG6.F
함부르크	HG6.HM
PNK	MAYNF

Mayne Pharma Group 티커	Mayne Pharma Group FIGI
MYX:AU	BBG000BLN683
MYX:AT	BBG000BLN6N6
HG6:GR	BBG000RJ7VB0
HG6:GF	BBG000RJ7VV8
HG6:GB	BBG000RJ7WT9
MYX:AH	BBG002F3HBP2
MAYNF:US	BBG0046WCJR0
MAYNF:PQ	BBG0046WCK51
MAYNF:UV	BBG0046WCK79
MYXEUR:EO	BBG00DKHGPK6
MYXEUR:XH	BBG00DKHGPN3
MYXEUR:XF	BBG00DKHGPQ0
MYXEUR:XE	BBG00DKHGPS8
MYXEUR:XJ	BBG00DKHGPT7
MYXEUR:XL	BBG00DKHGPV4
MYXEUR:XG	BBG00DKHGPW3
MYXEUR:XO	BBG00DKHGPX2
MYXEUR:XS	BBG00DKHGQ15
MYXEUR:XA	BBG00DKHGQ24
MYXEUR:E1	BBG00DKHGQ33
MYXEUR:XT	BBG00DKHGQ42
MYXEUR:XW	BBG00DKHGQ51
MYXEUR:XU	BBG00DKHGQ60
MYXEUR:XV	BBG00DKHGQ79
MYXEUR:EU	BBG00DKHGQ97
MYXEUR:XX	BBG00JN8JLH0
MYXAUD:X2	BBG00JSC5HS8
MYXAUD:XB	BBG00JSC5HT7
MYXAUD:XH	BBG00JSC5HW3
MYXAUD:XF	BBG00JSC5HY1
MYXAUD:XE	BBG00JSC5J04
MYXAUD:XJ	BBG00JSC5J13
MYXAUD:XL	BBG00JSC5J22
MYXAUD:XG	BBG00JSC5J31
MYXAUD:XO	BBG00JSC5J40
MYXAUD:XS	BBG00JSC5J86
MYXAUD:XA	BBG00JSC5J95
MYXAUD:E1	BBG00JSC5JB2
MYXAUD:XT	BBG00JSC5JC1
MYXAUD:XW	BBG00JSC5JD0
MYXAUD:XU	BBG00JSC5JF8
MYXAUD:XV	BBG00JSC5JG7
MYXAUD:XM	BBG00JSC5JH6
MYXAUD:XQ	BBG00JSC5JK2
MYXAUD:XX	BBG00JSC5JL1
MYXAUD:XZ	BBG00JSC5JM0
MYXAUD:EU	BBG00JSC5JP7

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
0	0	0	0	36	50	52	84	143	141	267	572	530	526	457	401	157	190	395	438	480	562
-	-	-	-	-	38.89	4.00	61.54	70.24	-1.40	89.36	114.23	-7.34	-0.75	-13.12	-12.25	-60.85	21.02	107.89	10.89	9.59	17.08
-	-	-	-	47.22	46.00	44.23	46.43	52.45	56.03	63.67	56.82	53.58	60.08	46.39	45.39	47.77	47.37	56.96	51.37	46.88	40.04
0	0	0	0	17	23	23	39	75	79	170	325	284	316	212	182	75	90	225	0	0	0
0	-1	-3	-3	3	1	6	-2	21	7	37	88	-133	-279	-92	-208	-281	117	-174	-19	-4	19
-	-	200.00	-	-200.00	-66.67	500.00	-133.33	-1,150.00	-66.67	428.57	137.84	-251.14	109.77	-67.03	126.09	35.10	-141.64	-248.72	-89.08	-78.95	-575.00
29.4	62	106.8	106.8	178.7	215.1	214.6	443.3	645.6	715.45	858	73.02	73.14	73.75	76.47	78.58	82.3	82.18	79.62	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커MYX.AX

ISINAU000000MYX0

WKNA1C821

Mayne Pharma Group 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Mayne Pharma Group 주가 이력

Mayne Pharma Group 주식 매출, EBIT, 이익 AU000000MYX0 · A1C821

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Mayne Pharma Group 매출, 이익 및 EBIT 역사

Mayne Pharma Group 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Mayne Pharma Group 주식 마진 AU000000MYX0 · A1C821

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Mayne Pharma Group 마진 역사

Mayne Pharma Group 주식 매출, EBIT, 주당 순이익 AU000000MYX0 · A1C821

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Mayne Pharma Group 매출, 이익 및 EBIT 주당 역사

Mayne Pharma Group 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

Mayne Pharma Group Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Mayne Pharma Group 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

Mayne Pharma Group 주식 수량 AU000000MYX0 · A1C821

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Mayne Pharma Group 주식 분할

Mayne Pharma Group 주식 배당금 AU000000MYX0 · A1C821

배당금

배당금에 대한 개요

해석 및 사용

투자 전략

Mayne Pharma Group 배당금 내역

Mayne Pharma Group 주식 배당률 AU000000MYX0 · A1C821

배당비율

연간 배당비율이란 무엇인가요?

데이터 해석 방법

티커
MYX.AX

ISIN
AU000000MYX0

WKN
A1C821